1 Feb 2022 07:00
C4X Discovery Holdings plc
("C4XD", "C4X Discovery" or the "Company")
Block Listing Return
1 February 2022 - C4X Discovery Holdings plc (AIM: C4XD), a pioneering Drug Discovery company, makes the following notification pursuant to AIM Rule 29 and Schedule Six of the AIM Rules for Companies, regarding its existing block listing (excluding the additional block listing applications above and those block listings that have now been cancelled):
Name of applicant: | C4X Discovery Holdings plc | |||
Name of scheme: | Warrants | |||
Period of return: | From: | 1 July 2021 | To: | 31 January 2022 |
Number and class of share(s) (amount of stock / debt securities) originally listed and the date of admission: | 106,964,288 ordinary shares of £0.01 each in the Company admitted to trading on 6 July 2021 | |||
Balance of unallotted securities under scheme(s) from previous return: | 106,964,288 ordinary shares | |||
Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for): | Nil | |||
Less: Number of securities issued/allotted under scheme(s) during period: | 2,200,000 | |||
Equals: Balance under scheme(s) not yet issued/allotted at end of period: | 104,764,288 | |||
Name of contact: | Brad Hoy |
Telephone number of contact: | +44 (0)203 198 0027 |
Contacts
C4X Discovery Holdings | |
Mo Noonan, Communications | +44 (0)787 6444977 |
Panmure Gordon (UK) Limited (NOMAD and Broker) | |
Freddy Crossley, Emma Earl (Corporate Finance) | +44 (0)20 7886 2500 |
Rupert Dearden (Corporate Broking) | |
C4X Discovery Media - Consilium Strategic Communications | |
Mary-Jane Elliott, Chris Gardner, Matthew Neal | +44 (0)203 709 5700 |
Notes to Editors:
About C4X Discovery
C4X Discovery ("C4XD") is a pioneering Drug Discovery company combining scientific expertise with cutting-edge Drug Discovery technologies to efficiently deliver world leading medicines, which are developed by our partners for the benefit of patients. We have a highly valuable and differentiated approach to Drug Discovery through our enhanced DNA-based target identification and candidate molecule design capabilities, generating small molecule drug candidates across multiple disease areas including inflammation, oncology, neurodegeneration and addictive disorders. Our commercially attractive portfolio ranges from early stage novel target opportunities to late stage Drug Discovery programmes ready for out-licensing to partners and we have two commercially partnered programmes with one candidate in clinical development.
We collaborate with leading pharmaceutical and life sciences companies to enrich our expertise and take our assets through pre-clinical and clinical development. Through early-stage revenue-generating licensing deals, we realise returns from our high value pre-clinical assets which are reinvested to maximise the value of our Drug Discovery portfolio.
C4XD.L (C4XD)